---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-049073"
form_type: "8-K"
ticker: "HSCS"
cik: "0001468492"
company_name: "HeartSciences Inc."
filed_at: "2023-09-21T23:59:59+00:00"
generated_at: "2026-06-10T10:34:41.516982+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# HeartSciences signs definitive license agreements with Icahn Mount Sinai for AI ECG algorithms and data access

## Summary
- Entered into 11 license agreements for 13 algorithms, 2 data science methods, and 3 patent filings related to AI ECG analysis.
- Mount Sinai will receive 15% of HeartSciences' common stock upon closing of a $5M financing, plus warrants for 914,148 shares at $0.5060.
- Royalties: low-single digit percentages of annual net sales of licensed products; sublicense revenue share also required.
- Also signed MOU for de-identified data access, ongoing research, and evaluation of HeartSciences' MyoVista wavECG device.
- HeartSciences plans to develop a cloud-based, device-agnostic platform to deploy algorithms broadly.

## SEC filing metadata
- accession: 0000950170-23-049073
- form_type: 8-K
- ticker: HSCS
- cik: 0001468492
- company_name: HeartSciences Inc.
- filed_at: 2023-09-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1468492/000095017023049073/0000950170-23-049073-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1468492/000095017023049073/hscs-20230920.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-049073
- JSON: https://secwatch.observer/filing/0000950170-23-049073.json
- Plain text: https://secwatch.observer/filing/0000950170-23-049073.txt

## Key facts
- Material Agreements
  HeartSciences Inc. entered into License Agreements with Icahn School of Medicine at Mount Sinai (effective 2023-09-20).
  - Action: entry
  - Agreement: license
  - Counterparty: Icahn School of Medicine at Mount Sinai
  - Effective: 2023-09-20
  source text: On September 20, 2023, Heart Test Laboratories, Inc. (the “Company”) entered into several definitive license agreements (each a “License Agreement” and collectively, the “License Agreements”) with Icahn School of Medicine at Mount Sinai (“Mount Sinai”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1468492/000095017023049073/0000950170-23-049073-index.htm
- Material Agreements
  HeartSciences Inc. entered into Securities Purchase Agreement with Icahn School of Medicine at Mount Sinai (effective 2023-09-20).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Icahn School of Medicine at Mount Sinai
  - Effective: 2023-09-20
  source text: on September 20, 2023, the Company and Mount Sinai entered into a Securities Purchase Agreement (the “ Securities Purchase Agreement”), pursuant to which the Company agreed to sell to Mount Sinai as of the Closing Date (as defined below)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1468492/000095017023049073/0000950170-23-049073-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.